This review concluded that mycophenolate mofetil used with a calcineurin inhibitor conferred a clinical benefit over azathioprine by reducing the risk of acute rejections and possibly reducing graft loss in patients receiving kidney transplants. This was a well-conducted review, but these conclusions should be treated cautiously given the poor quality of most of the evidence.
Study selection
Randomised controlled trials (RCTs) that compared mycophenolate mofetil with azathioprine as immunosuppressive agents in renal transplant recipients were eligible for inclusion. Trials that evaluated other types of transplant, or that changed more than one immunosuppressant agent between groups, or where randomisation occurred after the time of transplantation, were excluded.
Outcomes of interest were acute rejection incidence, patient survival, graft survival, graft function and side effects (malignancy, infection, gastrointestinal and haematological problems).
The included trials compared varying doses of azathioprine (between 1mg/kg/day to 150mg/day) with varying doses of mycophenolate mofetil (between 1g/day and 3g/day). All patients were also taking a calcineurin inhibitor that included cyclosporine A micro-emulsion, sandimmune or tacrolimus.
Studies were selected by two reviewers independently, with disagreements resolved by consensus.
Assessment of study quality
Trial quality was assessed using the Jadad scale that included randomisation, blinding and reporting of withdrawals. A score of 3 or more out of 5 points was considered good quality. Extra questions covering allocation concealment and description of blinding were added. Study quality was assessed by two reviewers independently, with disagreements resolved by discussion.
Data extraction
Dichotomous outcomes were extracted as relative risks (RR), continuous outcomes as mean differences (MD), and time to event outcomes as hazard ratios (HR), with their corresponding 95% confidence intervals (CI).
Data were extracted by two reviewers and checked at random by a third.
Methods of synthesis
Trials were pooled in either fixed-effect or random-effects meta-analyses. Heterogeneity was measured using the I statistic. If hazard ratios were not reported, they were estimated using standardised recalculation methods. Subgroup analyses were used to compare drugs for patients on different calcineurin inhibitors and for mycophenolate mofetil dose (below 2g/day, 2g/day or over) using a statistical test of interaction. Sensitivity analyses repeated the models using only moderate to high quality trials (scoring 2 or more points) and investigated the impact of imputing missing data. Publication bias was assessed using funnel plots.
Results of the review
Nineteen RCTs (n=3,143 patients) were included in the review. Trial quality was poor, with only two trials scoring 3 or more on the Jadad scale. Only two trials reported adequate allocation concealment and seven used an intention-to-treat analysis. Duration of follow-up ranged from six to 60 months.
Acute rejection: Mycophenolate mofetil significantly reduced the risk of acute rejection compared with azathioprine (RR 0.62, 95% CI 0.55 to 0.70; 17 RCTs; I 2 =6.8%). Subgroup analyses showed that the risk reduction of acute rejection was greater in patients receiving sandimmune (RR 0.53) than microemulsions (RR 0.70); this was also the case in patients receiving higher doses (3g/day) of mycophenolate mofetil (RR 0.48) compared with lower doses (2g/day or less) (RR 0.66). Sensitivity analyses of higher quality trials did not alter the results. There was some evidence of publication bias.
Patient and graft survival: Mycophenolate mofetil reduced the hazard of graft loss (HR 0.76, 95% CI 0.59 to 0.98; 11 RCTs; I 2 =0%) There were no significant differences for patient survival or graft loss, or between subgroups. There was no evidence of publication bias. When the analysis was repeated for higher quality trials, the results were no longer statistically significant, but only three trials were included. There was no evidence of a difference between mycophenolate mofetil and azathioprine for patient survival or graft loss, excluding patient death with a functioning graft.
Graft function: Graft function measured by serum creatinine showed no overall difference between groups, but the observed heterogeneity was moderate (I 2 =40.3%). There was no evidence of a difference in the glomerular filtration rate.
Side effects: Mycophenolate mofetil increased the risk of diarrhoea (RR 1.57, 95%CI 1.33 to 1.86; six RCTs; I 2 =1.5%), but there were no differences between mycophenolate mofetil and azathioprine for vomiting or nausea or for more severe side effects (infections, anaemia, leukopenia or malignancy).
